5 Lessons From FDA’s First Biosimilar Review

Lisa Mueller, partner in Michael Best’s Intellectual Property and Chair of the Life Sciences and Chemical Practice Groups and Laura Opperman, Ph.D., a Patent Scientist in the Intellectual Property Practice group, gave input for a Law360 article titled, “5 Lessons From FDA’s First Biosimilar Review – Law360,” on January 8, 2015. To view the full article, click here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s